19-11-2020 дата публикации
Номер: US20200360514A1
There is provided a novel vaccine adjuvant, and more specifically, a vaccine adjuvant for stimulating a T lymphocyte-specific immune response, which includes an IL-12 protein and an IL-21 protein as active ingredients, or includes the polynucleotide encoding an IL-12 protein and the polynucleotide encoding an IL-21 protein as active ingredients. 1. A vaccine adjuvant for stimulating a T lymphocyte-specific immune response , comprising a polynucleotide encoding an IL-12 protein and a polynucleotide encoding an IL-21 protein as active ingredients.2. The vaccine adjuvant of claim 1 , wherein the vaccine adjuvant comprises at least one selected from the group consisting of:one to three vectors, each of which comprise: polynucleotides that respectively encode a p35 chain (IL-12p35) and a p40 chain (IL-12p40) that consist of the IL-12 protein; and a polynucleotide that encodes the IL-21 protein; anda mRNA molecules, each of which encode the IL-12p35, IL-12p40, and IL-21 proteins.3. The vaccine adjuvant of claim 1 , which promotes a T lymphocyte-specific immune response without inducing a B lymphocyte-specific immune response.4. The vaccine adjuvant of claim 1 , wherein the IL-12p35 protein consists of an amino acid sequence of SEQ ID NO: 1.5. The vaccine adjuvant of claim 1 , wherein the IL-12p40 protein is human IL-12p40 consisting of an amino acid sequence of SEQ ID NO: 2.6. The vaccine adjuvant of claim 1 , wherein the IL-21 protein is human IL-21 consisting of an amino acid sequence of SEQ ID NO: 3.7. The vaccine adjuvant of claim 1 , further comprising at least one among:a MIP-1α gene construct, in which a polynucleotide encoding the MIP-1α protein is operably linked to a promoter;a complex gene construct, in which a polynucleotide encoding the MIP-1α protein is operably linked to at least one among the IL-12p35, IL-12p40m, and IL-21 proteins, by a polynucleotide encoding an internal ribosome entry site (IRES) or linker peptide; anda mRNA molecule encoding MIP-1α ...
Подробнее